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Background: Immunotherapy in the treatment of metastatic melanoma and renal cell carcinoma can produce
durable therapeutic responses, which may improve survival. We aimed to identify clinical characteristics and
biomarkers associated with response to high-dose interleukin-2 therapy (IL-2) in patients with metastatic melanoma
and renal cell carcinoma treated at an academic community hospital.
Patients/Methods: We retrospectively analyzed clinical variables and biomarkers of 50 consecutive metastatic
melanoma or renal cell carcinoma patients treated at our institution with IL-2 during 2004 – 2012. We evaluated
clinical characteristics: metastatic sites of disease, prior therapies, number of IL-2 doses per cycle, response duration,
autoimmune phenomena, and peak fever, as well as laboratory biomarkers: baseline LDH, platelet nadir, and baseline
and highest absolute lymphocyte count (ALC). Survival outcomes were calculated using Kaplan-Meier curves.
Results: Variables differing between responders (clinical benefit group) and non-responders (no clinical benefit group)
in metastatic melanoma included platelet nadir during treatment (p = 0.015), autoimmune phenomena (p = 0.049),
and in renal cell carcinoma, platelet nadir (p = 0.026). There were no significant differences between number of doses
of IL-2 received per cycle and response in either cancer subtype. Clinical benefit occurred in 25% of patients (9/36)
when IL-2 was given as first-line therapy. Median overall survival for the clinical benefit group from the initiation of IL-2
to death or last follow-up was 61 months versus 17 months for the no clinical benefit group (p < 0.001) for metastatic
melanoma. In renal cell carcinoma overall survival for clinical benefit patients was 48 months versus 17 months.
No treatment-related deaths occurred.
Conclusions: High-dose IL-2 can be safely administered by an experienced team in a non–intensive care oncology
unit. The clinical benefit group developed autoimmune phenomena (melanoma patients), lower platelet nadir, and on
average, received the same number of IL-2 doses as the no clinical benefit group, suggesting a response relationship
to the patient’s baseline immune status. Further investigation of immune predictors of response may be useful to select
appropriate patients for this therapy.
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As the incidence of cutaneous melanoma has risen
incrementally in the United States, it has become a focus
of public health concern. In 2014, an estimated 76,100
persons will be diagnosed with melanoma, resulting in
9,710 estimated deaths (Cancer Facts and Figures 2014).
Kidney and renal pelvis cancers accounted for 63,920
new cases with 13,860 deaths (Cancer Facts and Figures
2014). Survival rates are largely dependent on the stage
of disease at initial diagnosis. Prior to 2011, treatment
options had been limited and, overall, disappointing for
stage IV melanoma with a median survival of less than
1 year (Agarwala 2009). Although the advent of multi-
targeted tyrosine kinase inhibitors has significantly im-
proved survival in patients with metastatic renal cell
carcinoma (mRCC), the median overall survival during
the time period of our study was less than 24 months
(Choueiri et al. 2007).
A new paradigm for primary systemic treatment for
metastatic melanoma has shifted toward immunotherapy,
including IL-2 and anti-CTLA4 monoclonal antibody
(ipilimumab) as well as programmed cell death 1 antibody
(anti-PD1), and molecularly-targeted therapies (BRAF or
MEK inhibitors). Current MM and mRCC treatments are
limited in curative potential and are generally palliative.
High-dose interleukin-2 (IL-2) is FDA-approved for the
treatment of MM and mRCC and is the only potentially
curative therapy that exists for both of these diseases. IL-2
immunotherapy, when used for treatment of mRCC, has
demonstrated an overall response rate (ORR) of approxi-
mately 14%, with 5% of responders having a complete
response (CR) (Fyfe et al. 1995). When used in the treat-
ment of MM the ORR is 17%, with 6 – 7% of patients
achieving a CR (Rosenberg et al. 1994). Currently there is
no way to determine prior to the initiation of therapy
which patients will experience complete response and
which patients are most likely to benefit from treatment.
Herein we detail our single-institutional experience at
Lehigh Valley Health Network in a retrospective analysis
of 50 consecutive patients with MM or mRCC treated
with high-dose IL-2 from August 2004 – August 2012.
Our aim was to compare the subset of patients who
derived clinical benefit to those patients without apparent
clinical benefit as determined by overall survival in
months from the initiation of IL-2 therapy. This compari-
son can be used to better delineate patient characteristics
and report patterns in IL-2–treated patients that may be
correlated to durable responses as well as aid in selecting
patients who are most likely to respond to IL-2 therapy.
Our exploratory analyses included pre-treatment and
treatment-related patient factors that may be associated
with treatment response. Our observations will add to the
growing body of knowledge in targeted, personalized can-
cer care in MM and mRCC. Additionally, we demonstratethat this treatment, when performed under a controlled
environment, can be safely administered in an academic
community hospital setting. Selection of therapy must
account for patient characteristics, toxicities and clinical
endpoints. The aim of our study was to better define prog-
nostic variables with response to IL-2 in the metastatic
setting and to compare specific characteristics of the clin-
ical benefit group versus those without clinical benefit.
Patients and methods
Study design and patient selection
A retrospective analysis was performed on a cohort of
50 consecutive patients with MM or mRCC treated with
high-dose IL-2 between August 2004 and August 2012
at Lehigh Valley Health Network, Allentown, Pennsylvania.
Our aim was to review our experience in using IL-2 in MM
and mRCC patients and to report patterns in IL-2 treated
patients who experienced significant survival benefit
of >1 year. Evaluation of responses was based on RECIST
criteria (Eisenhauer et al. 2009). Patients with oligometa-
static stable disease or partial response at the end of ther-
apy were considered for metastectomy on the basis of
clinical judgment. Patients rendered disease-free either by
IL-2 alone or IL-2 plus metastectomy or patients with
durable partial response for >1 year were considered to
have “clinical benefit.” Within the clinical benefit group, 2
of the patients had mRCC and 8 had MM.
We additionally report a safety and toxicity analysis of
IL-2 therapy when used in an academic community
hospital setting. Absolute inclusion criteria for IL-2 treat-
ment included histologically confirmed MM or mRCC
(stage IV) based on the tumor, node, metastasis (TMN)
criteria, Eastern Cooperative Oncology Group (ECOG)
performance score of 0 – 1, magnetic resonance imaging
or contrast computed tomography of the brain negative
for metastases or with small, asymptomatic or treated
metastases, liver function, thyroid stimulating hormone
and comprehensive metabolic profile within normal limits,
creatinine ≤ 1.5 mg/dL, absolute neutrophil count ≥1500,
platelet ≥1000, normal cardiac function as measured by
stress test and ejection fraction >50% on echocardiog-
raphy or MUGA scan, pulmonary function tests within
normal limits to 75% of predicted values for age, no ische-
mic changes on electrocardiogram. Other relative criteria
included age <50 and no or minimal visceral disease
(exceptions made on case by case basis). In our clinical
benefit group, none of the patients had documented
brain metastases prior to IL-2 treatment. In the entire
cohort, none of the patients had “active” brain metastases
prior to IL-2 therapy.
Ethics statement
The study was approved by Lehigh Valley Health Network’s
Institutional Review Board (IRB). All patient records and
Table 1 Institutional guidelines - relative and absolute
criteria for discontinuation of IL-2 therapy
System Relative criteria Absolute criteria
Cardiac Sinus tachycardia,
HR 120 – 130




















Infectious Strong clinical suspicion
or documented
Neurologic Mental status changes
Disorientation, vivid
dreams, emotional lability
Pulmonary Resting dyspnea >4 L oxygen needed
for saturations >95%




40% oxygen mask for
saturations >95%




80 – 160 mL/8 hour
Urine <80 mL/8 hour
Urine < 10 mL/hour
Creatinine ≥ 3 mg/dLUrine 10 – 20 mL/hour
Creatinine
2.5 – 2.9 mg/dL
Weight Gain 15% over baseline
In the occurrence of any relative criteria the dose is held, corrective action taken
and patient re-assessed at next scheduled time. Discontinue therapy if ≥ 3
relative criteria occur or for any one absolute criteria. Discontinue therapy if
pressors are needed for hypotension, neurological changes or the scheduled
dose has been held on 3 occasions.
HR = heart rate, EKG = electrocardiogram, PVC = premature
ventricular contraction).
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Data collection
Data were extracted from the medical record and in-
cluded age, gender, disease subtype (melanoma or renal
cell carcinoma), time from first day of IL-2 treatment to
death, time from stage IV diagnosis to death, metastatic
sites, baseline LDH, total number of IL-2 doses received,
total number of cycles of IL-2, average dose per cycle,
duration of response in months, autoimmune phenomena
(hypothyroidism, vitiligo, neuropathy), peak fever, intra-
cycle platelet nadir, baseline absolute lymphocytosis
(ALC) at the start of cycle 1, highest ALC (average peak
ALC across all cycles reported).
Toxicity
Toxicities were graded for each patient. In this study,
only grades 3 and 4 toxicities were reported, as defined
by the NCI Common Terminology Criteria for Adverse
Events 3.0 (Trotti et al. 2003).
Treatment
Treatment with HD IL-2 was given in a telemetry-
monitored, non–intensive care, specialized oncology unit.
HD IL-2 was delivered intravenously: 600,000 units/kg
over 15 minutes every 8 hours for a maximum of 14 doses
per cycle in accordance with strictly written protocols and
NCI guidelines for administration of HD IL-2. Continuous
cardiac monitoring occurred throughout the duration
of hospitalization. Hemodynamics were assessed every
4 hours and every 30 minutes after IL-2 infusion until a
dose-limiting factor precluded further treatments. Patients
were closely monitored for side effects and full doses were
held or administered at 8-hour intervals on the basis of
the presence or absence of relative and absolute criteria as
defined by published and institutional guidelines (Table 1).
After completion of a cycle of treatment (cycle 1), patients
were re-evaluated and admitted in 14 days for the next
cycle (cycle 2), administered in the same fashion (2 cycles
constituting one course of treatment). Re-staging occurred
6 weeks after every second cycle of IL-2; stable or
responding patients were eligible for a total of 3 courses of
treatment (6 cycles). Patients with evidence of tumor
regression or stable disease would then proceed to add-
itional courses of treatment—no sooner than 6 weeks but
no later than 8 weeks—following hospital discharge from
the prior course. Treatment was discontinued in patients
with evidence of progressive disease or untoward toxicity.
Response evaluation
Re-staging studies—including CT scans of the chest, abdo-
men and pelvis and (where indicated) magnetic resonance
imaging (MRI) of the brain—were performed at regularintervals (in general, after 2 cycles or within 2 months
from the initiation of therapy).
Statistical analysis
Descriptive statistics including means, standard deviations,
frequencies and percentages were calculated for the clinical
benefit and no clinical benefit groups. Continuous variables
were compared using Independent Student’s t-tests and
Mann–Whitney U. They are presented as mean ± standard
deviation and median (interquartile range), respectively.






Age 54.5 (49.0-59.25) 56.0 (43.5-64.5) .986*
Male 8 (100%) 22 (75.9%) .308†
BRAF Mutated 2/5 (40%) 9/19 (47.4%) 1.00†
Baseline ALC 1.50 (0.975-1.775) 1.30 (0.95-1.80) .842*
LDH 203.5 (164.0-415.75) 244.0 (187.0-542.5) .251*
Ulceration 2/6 (33.3%) 6/20 (30.0%) 1.00†
Prior Treatments 0/8 (0%) 7/29 (24.1%) 0.318†
Metastatic Subsets
IVA 2 (25%) 4 (13.8%) .591†
IVB 1 (12.5%) 6 (20.7%) 1.0†
IVC 5 (62.5%) 19 (65.5%) 1.0†
†Fisher’s Exact test (reported as frequency(percent)).
* Mann–Whitney U (reported as median (interquartile range)).
ALC: Absolute Lymphocyte Count.
LDH: Lactate Dehydrogenase.
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and Fisher’s Exact Tests. Categorical data are presented as
frequency (percent).
Overall survival was plotted on a Kaplan-Meier Curve.
Differences in group median survival were calculated
with the Log-Rank Test. Overall survival was calculated
from the date of initiation of IL-2 to death or last
follow-up by study closure.
All analyses were conducted using IBM SPSS Statistics
for Windows, version 21.0 (IBM Corp., Armonk, NY)
and MedCalc for Windows, version 13.0.1.0 (MedCalc
Software, Ostend, Belgium).
Results
We identified 10 patients (2 mRCC and 8 MM) who
responded to HD IL-2 therapy (clinical benefit group) and
40 who were non-responders (no clinical benefit group).
Fifty consecutive patients were analyzed and included
13 with renal cell carcinoma and 37 with melanoma.
There were no significant differences in age, gender,
prior treatments, ulceration or BRAF mutational status
in melanoma patients, sites of metastatic disease or
pretreatment laboratory values including baseline ALC
and LDH between the 2 groups. Demographic data can
be found in Tables 2 and 3.
In our cohort, we defined 10 patients with clinical
benefit and compared selected attributes of these patients
to those without apparent clinical benefit to identify
characteristics in MM and mRCC patients that may be
associated with response to immunotherapy. A small
subset of our cohort received prior therapies before
referral to our IL-2 center (14/50 patients) in the stage
IV setting. Within the mRCC group, more than half of
the patients (7/13) received other treatments prior to
IL-2 while only 7/37 of the patients with MM received
prior treatments. Renal cell patients receiving priorTable 2 Baseline characteristics renal cell carcinoma†






Age 47.0 (40.0) 53.0 (46.0-54.0) .641*
Male 2 (100%) 8 (72.7%) 1.0†
Baseline ALC 1.55 (1.30) 1.40 (0.80-1.70) .641*
LDH 277.5 (158.0) 209.0 (151.0-286.0) .641*
Prior Treatments 1/2 (50%) 6/11 (54.5%) 1.0†
Metastatic Subsets
Distant Nodes 1 (50%) 2 (18.1%) .423†
Lung +/− Distant Nodes 0 5 (45.5%) .487†
Visceral 1 (50%) 4 (36.4%) 1.0†
*Mann–Whitney U (reported as median (interquartile range)).
ALC: Absolute Lymphocyte Count.
LDH: Lactate Dehydrogenase.treatment included one who received interferon/bevaci-
zumab on a clinical trial and 6 who received targeted
therapies (sorafenib, sunitinib, temsirolimus, everolimus).
In our melanoma population, 2 received chemotherapy
alone (carboplatin/paclitaxel or temozolomide), 2 received
chemotherapy and targeted therapy, and 3 received mel-
anoma vaccines on clinical trials. Of the 14 patients who
received other therapies prior to IL-2, only one patient
was within the clinical benefit group (mRCC patient). The
group of 36 patients who received IL-2 as first-line
treatment for metastatic disease had 9 patients within
the clinical benefit group (25%). Although there ap-
peared to be a difference between prior therapies and
response to IL-2 therapy in our cohort, it did not reach
statistical significance in either cancer subtype (Tables 2
and 3) To date, 6/50 patients (12%) remain disease-free
and in complete remission. Two of these patients were
treated with IL-2 alone and 4 received IL-2 followed by
metastectomy. Three patients with partial or complete
response had eventual disease progression and died.
One patient who relapsed at year 3 is now on BRAF/
MEK-inhibition.
Treatment and outcome data can be found in Tables 4
and 5. Patients in the clinical benefit group for MM
were more likely to receive a greater number of HD IL-2
doses (33.0 versus 18.0, p =0.001) and a greater number
of total cycles (6.0 versus 2.0, p <0.001) than those in the
no clinical benefit group. In addition, the clinical benefit
group had a longer duration of therapy (26.0 versus
1 month, p <0.001). The no clinical benefit group had a
higher median platelet nadir (80.0 (69.5 – 133.0)) than the
clinical benefit group (50.0 (37.25 – 93.0)) p = 0.015. The
clinical benefit group showed a higher frequency of auto-
immune phenomenon (p = 0.049). For mRCC, the clinical






Total Doses 33.0 (29.0 – 41.75) 18.0 (12.5 – 28.0) .001*
Total Cycles 6.0 (5.0 – 6.0) 2.0 (2.0 – 4.0) <.001*
Doses per Cycle 6.4 (5.33 – 6.96) 7.0 (5.42 – 7.38) .502*
Duration (months) 26.0 (18.25 – 56.25) 1.0 (0 – 4.0) <.001*
Peak Fever (Celsius) 39.7 (38.5 – 40.3) 39.1 (38.4 – 39.3) .158*
Peak ALC 3.75 (2.85 – 5.425) 2.9 (1.9 – 4.05) .137*
Platelets 50.0 (37.25 – 93.0) 80.0 (69.5 – 133.0) .015*
Autoimmune
phenomenon
4 (50.0%) 4 (13.8%) .049†
Any Toxicity 5 (62.5%) 9 (31.0%) .215†
None 3 (37.5%) 20 (68.9%) .215†
Grade 3 3 (37.5%) 3 (10.3%) .101†
Grade 4 2 (25.0%) 6 (20.7%) .1.0†
Grade 5 – – –
Survived 6 (75.0%) 7 (24.1%) .006†
Survival Months 61.0 17.0 .001¥
†Fisher’s Exact test (reported as frequency (percent)).
*Mann–Whitney U (reported as median (interquartile range)).
¥Log-Rank Test (reported as median, censored data included).
ALC: Absolute Lymphocyte Count.






Total Doses 46.5 (38.0) 14.0 (10.0 – 22.0) <.026*
Total Cycles 6.0 (6.0) 2.0 (2.0 – 4.0) <.026*
Doses per Cycle 7.75 (6.33) 5.5 (5.0 – 6.75) .231*
Duration (months) 28.0 (23.0) 2.0 (0 – 4.5) <.026*
Peak Fever (Celsius) 39.3 (39.1 – 39.6) 38.9 (38.7 – 39.8) .641*
Peak ALC 5.3 (5.1) 3.4 (2.0 – 4.6) .103*
Platelets 49.0 (33.0) 109.0 (88.0 – 146.0) .026*
Autoimmune
phenomenon
1 (50.0%) 1 (9.1%) .295†
Any Toxicity 2 (100%) 3 (27.3%) .128†
None 0 8 (72.7%) .128†
Grade 3 2 (100%) 2 (18.2%) .077†
Grade 4 0 1 (9.1%) .1.0†
Grade 5 – – –
Survived 1 (50.0%) 6 (54.5%) 1.0†
Survival Months 48.0 17.0 .231¥
†Fisher’s Exact test (reported as frequency (percent)).
*Mann–Whitney U (reported as median (interquartile range)).
¥Log-Rank Test (reported as median, censored data included).
ALC: Absolute Lymphocyte Count.
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total cycles (p <0.026) and had a lower platelet nadir.
Seventy-five percent (6 patients) in the MM clinical
benefit groups versus 24.1% (7 patients) in the no clin-
ical benefit group were alive at study closure (p = 0.006).
For mRCC patients, one in the clinical benefit group
and 6 in the no clinical benefit group were alive at study
closure. Median overall survival for the entire cohort
was 22 months (p = 0.001) for metastatic melanoma and
48 months (p = 0.231) for mRCC. For MM, the median
overall survival was 61 months in the clinical benefit
group versus 17 months in the no clinical benefit group
(p = 0.001) (Figure 1). For mRCC, median survival was
48 months in the clinical benefit group versus 17 months
in the no clinical benefit group (Figure 2).
Discussion
MM and mRCC portend an overall poor prognosis. The
5-year survival rates for mRCC and MM are 12% and
15%, respectively (American Cancer Society 2014). More-
over, the incidence of melanoma has been steadily increas-
ing over the past 30 years (Howlader et al. 1975). For
MM, the efficacy of traditional chemotherapeutic agents is
mediocre (Trotti et al. 2003). For this reason, improved
therapies are needed. Our general treatment philosophy
for stage IV disease is immunotherapy—first-line in
suitable candidates—followed by targeted therapy and
chemotherapy as later options. This is aligned with the
2013 Society for Immunotherapy of Cancer Consensus
statement (Kaufman et al. 2013). The consensus panel has
recognized several systemic therapies for unresectable
stage IV melanoma, including high-dose IL-2, ipilimumab
and, in BRAF-mutated tumors, vemurafenib, dabrafenib
(BRAF inhibitors) and trametinib (MEK inhibitor), as
well as referral for ongoing clinical trials. However, IL-2
immunotherapy has emerged as first-line therapy for stage
IV melanoma in patients with good performance status
and eligibility per institutional guidelines. In patients with
BRAF-mutated melanoma and good performance status, a
BRAF inhibitor is reserved for unequivocal evidence of
disease progression after immunotherapy. Evaluation for
surgical resection of metastases is advisable for all pa-
tients, pre- and post-immunotherapy treatment (Kaufman
et al. 2013). We demonstrate that IL-2 can be safely
administered at centers with teams experienced in the
delivery of treatment and management of side effects
and toxicities. Furthermore, in carefully selected patients,
IL-2 immunotherapy can produce durable therapeutic
responses including prolonged disease-free survival and,
in some instances, cure.
We identified several prognostic indicators of response
to IL-2 treatment. We found for both MM and mRCC
that the number of doses per cycle was not significant.
However, total doses and cycles received throughout the
Figure 1 Kaplan Meier survival curve metastatic melanoma.
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5). The most provocative finding is the trend toward
greater clinical efficacy of high-dose IL-2 in the first-line
setting (25% of patients in clinical benefit group) as
opposed to later-line therapy, despite comparable per-
formance status for both groups. Our analyses did not
reveal statistical significance although our study most
likely is not powered to sufficiently detect true differences.
Our observations suggest a relationship between degree
of thrombocytopenia and clinical response to IL-2 treat-
ment. A few other studies have evaluated the relationship
between platelet nadir and response to IL-2 therapyFigure 2 Kaplan Meier survival curve renal cell carcinoma.with conflicting results (American Cancer Society 2014;
Rosenberg et al. 1998; Klapper et al. 2008; MacFarlane
et al. 1995; Royal et al. 1996; Bael et al. 2004). Some stud-
ies (American Cancer Society 2014; Rosenberg et al. 1998;
MacFarlane et al. 1995) have shown no significant associ-
ation between degree of thrombocytopenia and response
while others (Klapper et al. 2008; Royal et al. 1996; Bael
et al. 2004) have demonstrated an association between
platelet nadir and response. The precise mechanism of
development of marked thrombocytopenia in association
with response to IL-2 has not been conclusively eluci-
dated. Proposed mechanisms include more adept platelet
Saraceni et al. SpringerPlus  (2015) 4:118 Page 7 of 8activation through the inflammatory cascade or mediation
of an antibody-producing immune response (MacFarlane
et al. 1995; Bael et al. 2004). The latter has been suggested
as platelets share common antigens with melanoma tumor
cells including glycoprotein IIb/IIIa, CD63 and vitronectin
receptor αVβ3. Antibody production against these common
antigens may produce an autoimmune thrombocytopenia
and concurrent anti-tumor effect (Bael et al. 2004).
Autoimmune phenomena are a well-documented conse-
quence of immunotherapy (Phan et al. 2001; Rosenberg
and White 1996; Krouse et al. 1996; Hodi et al. 2010) and
have been correlated with survival benefit (Phan et al. 2001;
Rosenberg and White 1996; Krouse et al. 1996). Immuno-
regulatory mechanisms underlying treatment-induced auto-
immunity to self (disruption of immunologic tolerance to
normal antigens) and the anti-tumor response is an active
area of current research (Jiang and Chess 2006). These
mechanisms have not been fully elucidated. In our study,
development of autoimmune phenomena in metastatic
melanoma was associated with response to IL-2.
IL-2 treatment-related toxicities, including systemic
capillary leak syndrome, a cascade of plasma extravasation
and vascular collapse, limit its delivery in clinical practice.
In our cohort, serious toxicities included gastrointestinal
bleeding in 2 patients (1 patient with a bleeding gastric
metastasis and the other patient with a duodenal ulcer
bleed after cycle 5 of treatment), acute pancreatitis in one
patient secondary to a pancreatic metastasis, venous
thrombosis in 2 patients (1 upper extremity DVT and 1
lower extremity DVT), and arrhythmia (1 patient with
paroxysmal atrial fibrillation and 2 patients with non-
sustained ventricular tachycardia). In addition, one patient
developed grade-3 delayed autoimmune angioedema
and uticaria. Serious grade-4 toxicities included acute
renal failure (1), hepatotoxicity (1), hypotensive shock
(1), congestive heart failure/ pleural effusion (1). Among
these, there were 3 intensive care unit (ICU) transfers.
Overall, the 3 ICU transfers were able to be managed with
aggressive medical measures. The other patients had
uneventful recovery from their toxicities with supportive
care. There were no treatment-related deaths. An interest-
ing observation was the absence of any peripherally
inserted central catheter (PICC) line-related infections or
overt bacteremia despite 173 admissions with PICC-line
placement for IL-2 therapy.
Limitations to our study include a small cohort of
patients included in a retrospective analysis. This is
particularly true in our mRCC subset where statistical
analysis would likely be more robust with a larger sam-
ple size. There may be differences in responding patients
although our study may not be powered to detect such
differences. Another limitation of our study is incomplete
data on both BRAF mutational status and ulceration in
melanoma patients. In the early study period, BRAFmutation status was not routinely tested and targeted
therapies had not received FDA approval. Both BRAF and
ulceration are adverse prognosticators and may potentially
bias the outcome measures. Prior studies, including pro-
spective trials (Phan et al. 2001; Klapper et al. 2008; Royal
et al. 1996; Tarhini et al. 2007), have validated our obser-
vations on a larger scale. Additionally, our survival data
are incomplete as many patients are still alive after the
study closure, which may underestimate the survival bene-
fit in clinical responders. Because our study represents a
small sample of patients, findings should be evaluated in
this context. Survival in our mRCC subset should be inter-
preted in the context of a limited sample size. The
provocative OS of 48 months in our 10 mRCC patients
treated with IL-2 may represent the controversial observa-
tion reported by others (Birkhauser et al. 2013) that
high-dose IL-2 may improve the duration of response
to salvage targeted therapy used at disease progression.
In summary, factors significantly associated with response
to IL-2 from our single institutional experience in treating
patients with MM or mRCC include development of auto-
immune phenomena including secondary hypothyroidism,
vitiligo and neuropathy in metastatic melanoma and lower
platelet nadir. Patients treated with IL-2 as first-line therapy
had a higher chance of clinical benefit. The number of
doses per cycle did not influence clinical benefit, and these
authors feel that it is unwise to push patients to receive a
higher number of doses in the face of significant toxicity.
We could not find a statistical significance to baseline LDH
and clinical benefit, as has been reported by others (Davar
et al. 2014). This may be due to our exclusion of patients
with very high LDH levels with active visceral metastases,
as the LDH levels were somewhat homogenous for our
treated group. We also demonstrate that IL-2 can be safely
and effectively administered in a community hospital set-
ting by using a systematic approach, which includes an
experienced health-care team that is knowledgeable in
delivering treatment and in managing treatment-related
side effects and toxicities. The delivery of IL-2 in a more
patient-friendly, non-ICU medical/surgical unit and treating
appropriate patients in the first-line setting may improve
the value and cost-effectiveness of this curative approach.
In our institution’s experience, treating appropriate patients
in the first-line setting demonstrated a 25% clinical benefit,
leading to a median survival of greater than 5 years in
metastatic melanoma (Figure 1), and 48 months in mRCC
(Figure 2) although our findings will need to be validated in
larger, prospective studies.
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